[{"id":"1387da34-72f6-46cd-8db5-48bc41fc9fe6","acronym":"AFNT211-22-101","url":"https://clinicaltrials.gov/study/NCT06105021","created_at":"2023-10-27T17:14:07.431Z","updated_at":"2025-02-25T13:55:42.802Z","phase":"Phase 1/2","brief_title":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","source_id_and_acronym":"NCT06105021 - AFNT211-22-101","lead_sponsor":"Affini-T Therapeutics, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFNT-211"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/06/2024","start_date":" 03/06/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-02-20"}]